No Data
No Data
Cautious Optimism: Q32 Bio's Strategic Shift to Focus on Bempikibart for Alopecia Areata
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Q32 Bio (QTTB) and Vaxcyte (PCVX)
Q32 Downgraded to Market Perform by BMO Over ADX-097
BMO Capital Downgrades Q32 Bio(QTTB.US) to Hold Rating, Cuts Target Price to $3
Q32 Bio Unveils Restructuring to Focus on Alopecia Areata Treatment; Shares Fall
Q32 Cut to Neutral by Piper on ADX-097 Discontinuation
Tree_in_Sydney : What??
Smokey93 OP Tree_in_Sydney : good potiental. did a big drop off bad news. but just hit the reversal trend! still a Bio stock analysts say worth 10-15. time to bounce back. but the swings big. very very low float and shares available.
Smokey93 OP Tree_in_Sydney : nice 5 day uptrend...
105033742 : Is there still a chance for holo...?
Smokey93 OP 105033742 : I gave up. doesn't seem it to be honest